Exchange Income Corporation Announces Voting Results for its 2025 Annual General Meeting of Shareholders
WINNIPEG, Manitoba--(BUSINESS WIRE)--Exchange Income Corporation (TSX: EIF) (the 'Corporation'), a diversified, acquisition-oriented company focused on opportunities in the Aerospace & Aviation and Manufacturing segments, announced today the voting results on the election of directors from its 2025 Annual General Meeting of Shareholders ("AGM").
A total of 16,410,022 common shares representing 31.97% of the Corporation's 51,323,387 issued and outstanding common shares were voted in connection with the AGM. Shareholders approved all items of business before the AGM, including the election of directors as follows:
Nominees
Votes in Favour
%
For
Votes Against
%
Against
Total
Brad Bennett
15,931,947
97.09%
478,075
2.91%
16,410,022
Gary Buckley
15,917,034
97.00%
492,988
3.00%
16,410,022
Polly Craik
16,327,097
99.49%
82,925
0.51%
16,410,022
Barb Gamey
16,341,518
99.58%
68,504
0.42%
16,410,022
Bruce Jack
15,951,562
97.21%
458,460
2.79%
16,410,022
Duncan Jessiman
15,035,586
91.62%
1,374,436
8.38%
16,410,022
Carmele Peter
15,970,120
97.32%
439,902
2.68%
16,410,022
Michael Pyle
15,981,967
97.39%
428,055
2.61%
16,410,022
Melissa Sonberg
14,994,736
91.38%
1,415,286
8.62%
16,410,022
Donald Streuber
15,908,038
96.94%
501,984
3.06%
16,410,022
Edward Warkentin
15,903,368
96.91%
506,654
3.09%
16,410,022
Expand
At the meeting, shareholders also voted in favour of the reappointment of PricewaterhouseCoopers LLP as the auditor of the Corporation until the close of the next annual meeting of shareholders; and the approval, on an advisory basis, of the Corporation's approach to executive compensation.
About Exchange Income Corporation
Exchange Income Corporation is a diversified acquisition-oriented company, focused in two segments: aerospace & aviation and manufacturing. The Corporation uses a disciplined acquisition strategy to identify already profitable, well-established companies that have strong management teams, generate steady cash flow, operate in niche markets and have opportunities for organic growth. For more information on the Corporation, please visit www.ExchangeIncomeCorp.ca. Additional information relating to the Corporation, including all public filings, is available on SEDAR+ (www.sedarplus.ca).
The statements contained in this news release that are forward-looking are based on current expectations and are subject to a number of uncertainties and risks, and actual results may differ materially. Many of these forward-looking statements may be identified by looking for words such as 'believes', 'expects', 'will', 'may', 'intends', 'projects', 'anticipates', 'plans', 'estimates', 'continues' and similar words or the negative thereof. These uncertainties and risks include, but are not limited to, external risks, operational risks, financial risks and human capital risks. External risks include, but are not limited to, risks associated with economic and geopolitical conditions, competition, government funding for Indigenous health care, access to capital, market trends and innovation, general uninsured loss, climate, acts of terrorism, armed conflict, labour and/or social unrest, pandemic, level and timing of government spending, government-funded programs and environmental, social and governance. Operational risks include, but are not limited to, significant contracts and customers, operational performance and growth, laws, regulations and standards, acquisitions (including receiving any requisite regulatory approvals thereof), concentration and diversification, maintenance costs, access to parts and relationships with key suppliers, casualty losses, environmental liability, dependence on information systems and technology, cybersecurity, international operations, fluctuations in sales prices of aviation related assets, fluctuations in purchase prices of aviation related assets, warranty, performance guarantees, global offset and intellectual property risks. Financial risks include, but are not limited to, availability of future financing, income tax matters, commodity risk, foreign exchange, interest rates, credit facility and the trust indentures, dividends, unpredictability and volatility of securities pricing, dilution and other credit risk. Human capital risks include, but are not limited to, reliance on key personnel, employees and labour relations and conflicts of interest.
Except as required by Canadian Securities Law, Exchange Income Corporation does not undertake to update any forward-looking statements; such statements speak only as of the date made. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by Exchange Income Corporation with the securities regulatory authorities, available at www.sedarplus.ca.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Devonian Appoints New Officers and Announces Grant of Stock Options
QUÉBEC CITY, June 09, 2025--(BUSINESS WIRE)--Devonian Health Group Inc. ("Devonian" or the "Corporation") (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, today announced the appointment of Dr. André Boulet as Chief Executive Officer of the Corporation, replacing Mr. Luc Gregoire who will continue in the new role of Executive Vice-President Strategy of the Corporation, effective June 9, 2025. "As we enter a new phase of development, we are fortunate to retain Luc's deep strategic insight and leadership in a role focused on long-term planning and innovation. As Executive Vice President of Strategy, he will continue to drive key initiatives, ensuring continuity and alignment with our mission while supporting the executive team through this important transition," stated Dr. Boulet, President & CEO of the Company. "I look forward to continuing to advise the executive team and help garner support from external stakeholders, as the Company sharpens its focus on its high potential anti-inflammatory clinical programs," said Luc Gregoire. The Corporation also announced that its board of directors has approved the grant of options to purchase common shares of the Corporation (the "Stock Options") primarily for a director of the Corporation and the Chief Financial Officer, both of whom joined the organization in the past few months. The Stock Options were granted at an exercise price of $0.15 for a period of 10 years from the date of grant, which ends on June 9, 2035. An aggregate of 438,596 Stock Options was granted to a director of the Corporation and an aggregate of 850,000 Stock Options was granted to employees of the Corporation. 50.33% of these Stock Options are exercisable immediately, 12.42 % shall vest upon the date that is 12 months from the date of issuance; 12.42 % shall vest upon the date that is 24 months from the date of issuance 12.42 % shall vest upon the date that is 36 months from the date of issuance and the remaining 12.42 % shall vest upon the date that is 48 months from the date of issuance. About Devonian Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. Devonian's core strategy is to develop prescription drugs for the treatment of inflammatory autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian's focus is further supported by a U.S. Food and Drug Administration set of regulatory guidelines favoring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines. Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare Inc., focused on selling prescription pharmaceutical products in Canada, under license from brand name pharmaceutical companies. Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability 'from the seed to the pill'. Devonian is traded publicly on the TSX Venture Exchange (the "Exchange") (TSXV: GSD) and on OTCQB exchange (OTCQB: DVHGF). For more information, visit Cautionary Note Regarding Forward-Looking Statements All statements, other than statements of historical fact, contained in this press release including, but not limited to those relating, the appointment of Ms. Krasteva as Chief Financial Officer and, generally, the above "About Devonian" paragraph, which essentially describes the Corporation's outlook, constitute "forward-looking information" or "forward-looking statements" within the meaning of certain securities laws, and are based on expectations, estimates and projections as of the time of this press release. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Corporation as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release. View source version on Contacts Devonian Health Group Inc. Dr. André BouletChief Executive OfficerTelephone: 1 (514) 248-7509E-mail: investors@ Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Afya Limited (the "Company") Notice of Annual General Meeting of the Company
NOVA LIMA, Brazil, June 09, 2025--(BUSINESS WIRE)--Notice is hereby given that an Annual General Meeting of the Company (the "AGM") will be held at the offices of Afya Participações S.A., Alameda Oscar Niemeyer, No. 119, 15th Floor, Vila da Serra, Nova Lima, Minas Gerais, Brazil, Zip Code: 34.006-056, and virtually by accessing the following link (password: afya2025), on the 24th day of June 2025 at 10:00 a.m. BRT, for the purpose of considering and, if thought fit, passing and approving the following resolutions: "As an ordinary resolution, that the Company's financial statements and the auditor's report for the fiscal year ended December 31, 2024 be approved and ratified." "As an ordinary resolution, that João Paulo Seibel de Faria be re-appointed as an independent director of the Company with immediate effect to hold office for a two year term in accordance with the Amended and Restated Articles of Association of the Company." "As an ordinary resolution, that Vanessa Claro Lopes be re-appointed as an independent director of the Company with immediate effect to hold office for a two year term in accordance with the Amended and Restated Articles of Association of the Company." "As an ordinary resolution, that Miguel Filisbino Pereira de Paula be re-appointed as an independent director of the Company with immediate effect to hold office for a two year term in accordance with the Amended and Restated Articles of Association of the Company." "As an ordinary resolution, that Marcelo Ken Suhara be re-appointed as an independent director of the Company with immediate effect to hold office for a two year term in accordance with the Amended and Restated Articles of Association of the Company." The AGM will also serve as an opportunity for shareholders to discuss Company affairs with management. Shareholders may participate in the AGM virtually by accessing the following link (password: afya2025). Participation by a shareholder in the AGM in this manner shall be treated as presence in person at the AGM and such shareholder shall be counted in a quorum and entitled to vote in accordance with Article 18.3 of the Articles of Association of the Company. The Board of Directors of the Company (the "Board") has fixed the close of business, BRT, on May 14, 2025, BRT, as the record date (the "Record Date") for determining the shareholders of the Company entitled to receive notice of the AGM or any adjournment thereof. The holders of record of the Class A common shares and the Class B common shares of the Company as at the close of business, BRT, on the Record Date are entitled to receive notice of and attend the AGM and any adjournment thereof. The Company's 2024 Financial Statements for the fiscal year ended December 31, 2024 was filed with the U.S. Securities and Exchange Commission on March 13, 2025 (the "Financial Statements"). Shareholders may obtain a copy of the Financial Statements, free of charge, from the Company's website at or by contacting the Company's Investor Relations Department by email at ir@ The Board recommends that shareholders of the Company vote "FOR" the resolutions at the AGM. Your vote is very important to the Company. Whether or not you plan to attend the AGM, please promptly complete, date, sign and return the proxy card attached to this Notice. By order of the Board /s/ Kay Kraft__________________ Kay Kraft Director June 9, 2025 Registered Office:c/o Maples Corporate Services LimitedPO Box 309, Ugland HouseGrand CaymanKY1-1104Cayman Islands *A form of proxy has been included with this Notice. NOTES IF YOU HAVE EXECUTED A STANDING PROXY, YOUR STANDING PROXY WILL BE VOTED AS INDICATED IN NOTE 2 BELOW, UNLESS YOU ATTEND THE AGM IN PERSON OR SEND IN A SPECIFIC PROXY. A proxy need not be a shareholder of the Company. A shareholder entitled to attend and vote at the AGM is entitled to appoint one or more proxies to attend and vote in his/her stead. Any standing proxy previously deposited by a shareholder with the Company will be voted in favour of the resolutions to be proposed at the AGM unless revoked prior to the AGM or the shareholder attends the AGM in person or executes a specific proxy. A form of proxy for use at the AGM is enclosed. Whether or not you propose to attend the AGM in person, you are strongly advised to complete and sign the enclosed form of proxy in accordance with the instructions printed on it and then deposit it (together with any power of attorney or other authority under which it is signed or a notarially certified copy of that power or authority) at the offices of Afya Participações S.A., Alameda Oscar Niemeyer, No. 119, 15th Floor, Vila da Serra, Nova Lima, Minas Gerais, Brazil, Zip Code: 34.006-056, or send copies of the foregoing by email to ir@ in each case marked for the attention of Renata Couto, Anibal Sousa and Rodrigo Proença, not later than 11:59 p.m. BRT on the business day prior to the date of the AGM or adjourned AGM in accordance with the Amended and Restated Articles of Association of the Company. Returning the completed form of proxy will not preclude you from attending the AGM and voting in person if you so wish. If two or more persons are jointly registered as holders of a share, the vote of the senior person who tenders a vote, whether in person or by proxy, shall be accepted to the exclusion of the votes of other joint holders. For this purpose seniority shall be determined by the order in which the names stand on the Company's register of shareholders in respect of the relevant shares. A shareholder holding more than one share entitled to attend and vote at the AGM need not cast the votes in respect of such shares in the same way on any resolution and therefore may vote a share or some or all such shares either for or against a resolution and/or abstain from voting a share or some or all of the shares and, subject to the terms of the instrument appointing any proxy, a proxy appointed under one or more instruments may vote a share or some or all of the shares in respect of which he is appointed either for or against a resolution and/or abstain from voting. No business shall be transacted at the AGM unless a quorum is present at the time when the meeting proceeds to business. One or more Members holding not less than one-third in aggregate of the voting power of all Shares in issue and entitled to vote, present in person or by proxy or, if a corporation or other non-natural Person, by its duly authorised representative, shall represent a quorum. View source version on Contacts Investor Relations Contact:Afya Limitedir@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
Devonian Appoints New Officers and Announces Grant of Stock Options
QUÉBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (' Devonian ' or the ' Corporation ') (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, today announced the appointment of Dr. André Boulet as Chief Executive Officer of the Corporation, replacing Mr. Luc Gregoire who will continue in the new role of Executive Vice-President Strategy of the Corporation, effective June 9, 2025. 'As we enter a new phase of development, we are fortunate to retain Luc's deep strategic insight and leadership in a role focused on long-term planning and innovation. As Executive Vice President of Strategy, he will continue to drive key initiatives, ensuring continuity and alignment with our mission while supporting the executive team through this important transition, ' stated Dr. Boulet, President & CEO of the Company. 'I look forward to continuing to advise the executive team and help garner support from external stakeholders, as the Company sharpens its focus on its high potential anti-inflammatory clinical programs,' said Luc Gregoire. The Corporation also announced that its board of directors has approved the grant of options to purchase common shares of the Corporation (the ' Stock Options ') primarily for a director of the Corporation and the Chief Financial Officer, both of whom joined the organization in the past few months. The Stock Options were granted at an exercise price of $0.15 for a period of 10 years from the date of grant, which ends on June 9, 2035. An aggregate of 438,596 Stock Options was granted to a director of the Corporation and an aggregate of 850,000 Stock Options was granted to employees of the Corporation. 50.33% of these Stock Options are exercisable immediately, 12.42 % shall vest upon the date that is 12 months from the date of issuance; 12.42 % shall vest upon the date that is 24 months from the date of issuance 12.42 % shall vest upon the date that is 36 months from the date of issuance and the remaining 12.42 % shall vest upon the date that is 48 months from the date of issuance. About Devonian Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. Devonian's core strategy is to develop prescription drugs for the treatment of inflammatory autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian's focus is further supported by a U.S. Food and Drug Administration set of regulatory guidelines favoring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines. Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare Inc., focused on selling prescription pharmaceutical products in Canada, under license from brand name pharmaceutical companies. Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability 'from the seed to the pill'. Devonian is traded publicly on the TSX Venture Exchange (the ' Exchange ') (TSXV: GSD) and on OTCQB exchange (OTCQB: DVHGF). For more information, visit Cautionary Note Regarding Forward-Looking Statements All statements, other than statements of historical fact, contained in this press release including, but not limited to those relating, the appointment of Ms. Krasteva as Chief Financial Officer and, generally, the above 'About Devonian' paragraph, which essentially describes the Corporation's outlook, constitute 'forward-looking information' or 'forward-looking statements' within the meaning of certain securities laws, and are based on expectations, estimates and projections as of the time of this press release. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Corporation as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Corporation disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.
